There is no cure for Crohn's disease. It is a long-term disease in which the immune system causes inflammation in the digestive tract, and about 1 million people in the U.S. have it. Medicines and surgery can calm the inflammation and keep people in remission, but they do not cure it. Since 2022 the FDA has approved three IL-23 blockers and an oral pill for adults, and on April 15, 2026 it approved Stelara for children 2 and older. Our view: a cure would need to reset the immune response in the gut, and no treatment does that yet. The progress is in longer-lasting remission and new drug targets such as TL1A.
This is Cure Checker's editorial assessment of published evidence, not medical advice. Care decisions belong with a gastroenterologist who treats Crohn's disease.
Please read first. This is an AI-generated hypothesis, written by Cure Checker's AI from published research. It is speculation, not an established finding. It is not a recommendation, not a prediction that a cure exists, and not medical advice. No doctors or scientists have reviewed it, and it may be wrong. Never start, stop, change or delay any treatment because of it. Talk with your gastroenterologist.
Could the immune response to gut-bacteria flagellin, which starts years before symptoms, be part of what keeps Crohn's coming back? If people treated strongly from diagnosis were tracked with a flagellin-antibody blood test (one that does not yet exist for this use), would those whose levels return to normal stay in remission longer after a supervised stop in a clinical trial?
What would prove it wrong: if these antibody levels do not fall with early treatment, or if people whose levels fall relapse just as often after stopping as those whose levels stay high.
Hypothesis written October 6, 2026. Cure Checker's AI will revisit it when major new evidence appears.
Newest first. Updated each morning as results, trial launches and papers are published.
A Japanese cohort study of 32 people with Crohn's and 33 healthy people used breath tests for small-intestinal bacterial overgrowth (SIBO). Hydrogen-type SIBO was found in 3 of 32 people with Crohn's (9.4%) before treatment and none of the healthy people, a difference that was not statistically significant. Three more tested positive after balloon widening of a narrowing or surgery in the ileum, bringing the total to 6 of 32 (18.8%). The authors say strictures may hide SIBO on the test, results should be read with caution, and the study was small.
In a randomized trial of 106 adults with Crohn's disease and short bowel narrowings (strictures), cutting the scar through a scope (endoscopic stricturotomy) led to fewer problems coming back at 1 year than balloon stretching: 30.1% vs 54.7%. Repeat procedures were 24.5% vs 49.1%. Surgery rates did not differ significantly (1.9% vs 11.3%), and side effects were similar. The authors call it promising in expert centers and say larger multicenter trials are needed.
A post hoc look at the 152 Chinese patients in the Phase 3 VIVID program. At week 52, 37.3% on mirikizumab vs 0% on placebo had an endoscopic response, and 41.0% vs 6.9% were in clinical remission (composite measures). Among those who continued, benefits were sustained through week 152, and no unexpected safety findings were seen. This was an exploratory subgroup analysis, and the paper says mirikizumab was approved in China for Crohn's in 2026.
In a small randomized crossover trial of 29 close relatives of people with Crohn's who had raised gut inflammation markers but no Crohn's diagnosis, 8 weeks of the "Tasty and Healthy" diet cut fecal calprotectin by half or more in 71% vs 27% on their usual diet. This is a prevention idea in people who do not have Crohn's. It does not treat the disease, and longer trials are needed.
AbbVie reported results from TARGET-CD, an open-label Phase 2a study of 300 adults with moderate to severe Crohn's disease, randomly assigned to the two-drug combination ABBV-466 (106), risankizumab alone (94) or trosunilimab alone (100). At week 12, endoscopic remission was 30.2% with ABBV-466, 21.3% with risankizumab and 18.0% with trosunilimab; at week 24 it was 40.5%, 22.4% and 20.0%. Serious side effects were about 9% to 10% in all three groups. It was open-label with about 100 people per group, the numbers come from the company, and ABBV-466 is still experimental.
Johnson & Johnson reported 48-week results from FUZION, a Phase 3 trial in people with Crohn's disease and fistulas (abnormal tunnels) near the anus. On the 100 mg every-8-weeks dose, the share with combined fistula remission (healed by exam and by scan) rose from 28% at week 24 to 35% at week 48. The 200 mg every-4-weeks dose was described as consistent, with no percentage given. More than 90% of people finished 48 weeks. No week-48 placebo number was given, it was shown as a late-breaking conference abstract, and the report comes from the maker.
In the open-label extension, people who stayed on mirikizumab reported lasting gains in quality of life at week 104. Quality-of-life response was reached by 85.0% of those who had an endoscopic response in the first year and 72.6% of those who did not. About 75% and 54% of those two groups were in symptom-based remission at two years. There was no placebo comparison at this stage, and several authors work for the maker, Eli Lilly.
At a gastroenterology meeting, researchers presented results from 289 adults with moderate to severe Crohn's disease, randomly assigned to injected risankizumab (191) or placebo (98). At week 12, 55% vs 29.6% were in clinical remission and 44% vs 14.3% had an endoscopic response (a visible improvement of the gut lining). Among people who continued to week 24, 67.2% vs 29.6% were in clinical remission. Side effects were reported as similar between the groups. The week 24 figures include only people who stayed in the study. This is a conference report, not yet a peer-reviewed paper, and the drug is made by AbbVie. The FDA has not yet decided on the injection regimen.
Johnson & Johnson reported week 144 results from the Phase 3 extension. Among people who stayed on treatment and had data at three years, 94% (100 mg every 8 weeks) and 91% (200 mg every 4 weeks) were in clinical remission, and 52% and 61% had endoscopic remission. About 74% were still on guselkumab at three years. These numbers leave out people who stopped treatment or changed dose, there was no placebo comparison at this point, and the report comes from the maker.
Researchers pooled 18 randomized trials (4,697 adults) for year-one results. For disease limited to the lower small intestine (ileum), only guselkumab beat placebo at keeping people in clinical remission at week 52. For disease limited to the colon, upadacitinib 30 mg ranked highest. No location differences were seen for the other drugs. It compares trials indirectly, so it supports discussing location with a doctor but is not proof.
In 30 adults with Crohn's disease, one stool transplant (fecal microbiota transplant, by colonoscopy) cleared the Crohn's-linked bacterium adherent-invasive E. coli from the gut lining in all 8 people who had it at the start and could be checked. No serious side effects were linked to the transplant in the first 12 weeks. There was no placebo group, so this shows the idea is feasible, not that it works as a treatment.
In the long-term extension of the Phase 2 GALAXI 1 trial, 97.7% of people still on guselkumab with data at week 240 were in clinical remission and 51.7% had endoscopic remission. Counting everyone who started, 46% were in clinical remission at week 240. No new safety concerns were reported.
In 139 adults, 48% on the 900 mg dose and 26% on 450 mg had an endoscopic response at week 14, compared with 13% on placebo. No safety concerns were found. In February, the companies reported that responses held through 44 more weeks of treatment (company press release). Phase 3 trials (STARSCAPE-1 and -2) are recruiting.
An updated network analysis of 94 randomized trials found high-certainty evidence that ustekinumab brings on remission, and moderate-certainty evidence for adalimumab (alone or with a purine drug) and guselkumab, among others. The authors call for more head-to-head trials and longer safety data.
Takeda said the FDA accepted its application for IV vedolizumab in children 2 and older with Crohn's disease or ulcerative colitis. A decision is expected in the first quarter of 2027.
AbbVie asked the FDA to approve starting Skyrizi with injections under the skin instead of IV infusions. The Phase 3 AFFIRM trial (289 people) met both main goals at week 12, according to the company. AbbVie expects a decision in 2026.
The FDA added moderate to severe Crohn's disease in children 2 and older to Stelara's label, based on the UNITI-Jr Phase 3 study. Side effects were similar to those seen in adults.
In 568 people with complex perianal fistulas, 48.8% on darvadstrocel and 46.3% on placebo reached combined remission at week 24, a difference too small to count. No new safety signals were seen.
A peer-reviewed paper reported that 73.4% of people were in clinical remission after two years of mirikizumab. Three-year results shown at the ECCO congress in February found remission held for most people who had responded in year one.
In an open-label randomized trial, 69.2% of people on a 5-day monthly fasting-mimicking diet had a clinical response after three cycles, compared with 43.8% on their usual diet. Gut-inflammation markers also fell. The authors call for more study.
Treatment aims to calm inflammation, prevent flares and keep people in remission. Biologic medicines, a daily pill, older immune-suppressing drugs, nutrition therapy and surgery all play a part.
Biologics that block the immune signal IL-23. Started by IV infusion or, for Tremfya, by injection under the skin, then continued as home injections. In the Omvoh trial, 53% were in remission at one year, compared with 36% on placebo.
A JAK-inhibitor tablet for adults whose Crohn's did not respond to, or who could not take, a TNF blocker. Since October 10, 2025 the label also allows it when TNF blockers are not advisable, after another approved treatment.
Blocks IL-12 and IL-23. Long used in adults, it was approved for children 2 and older in 2026, the first non-TNF biologic for that age group, according to its maker.
The oldest biologics for Crohn's. A 2026 Cochrane review of 94 trials found that adalimumab, especially with a purine drug such as azathioprine, is among the medicines that bring on remission.
Among people who stayed on Tremfya to week 240 and had data, 97.7% were in clinical remission. Counting everyone who started, 46% were. Omvoh's extension also showed remission held through three years in those who responded in year one.
Surgery treats blockages, fistulas and abscesses but does not cure the disease. For children, an all-liquid formula diet (exclusive enteral nutrition) can be used instead of steroids to bring on remission.
| Treatment | For | What it does |
|---|---|---|
| Corticosteroids | Flares, short term only | Quickly calm inflammation. Not for long-term use. |
| Immunosuppressants (e.g. azathioprine) | Keeping remission; often paired with biologics | Dampen the immune response. |
| TNF blockers (infliximab, adalimumab) | Moderate to severe disease | Block TNF, a key inflammation signal. |
| IL-23 and IL-12/23 blockers (risankizumab, mirikizumab, guselkumab, ustekinumab) | Moderate to severe disease | Block the IL-23 pathway that drives gut inflammation. |
| Upadacitinib (pill) | Adults after a TNF blocker, or when one isn't advisable | Blocks JAK enzymes inside immune cells. |
| Surgery | Blockages, fistulas, abscesses, or when medicines fail | Removes damaged bowel. Does not cure Crohn's. |
No supplement has been shown to cure Crohn's or replace its medicines. Stopping smoking is the strongest step on this list. We rate each by the strength of evidence.
Smoking may double the chance of getting Crohn's, and Crohn's & Colitis UK advises everyone with Crohn's to stop.
A Cochrane review found low-quality evidence that it may work better than steroids for bringing on remission in children. Done only with the care team.
One small, open-label 2026 trial in mild to moderate Crohn's was promising. It needs confirmation and should only be tried with medical supervision.
A 2020 Cochrane review found the evidence very uncertain for bringing on remission in Crohn's.
Two large, high-quality trials suggest it probably does not help keep Crohn's in remission. It can cause diarrhea.
A Cochrane review found its effects on Crohn's uncertain, with no firm conclusions on benefit or safety.
Be careful: don't stop or swap prescribed medicines for supplements without talking to your care team. Severe belly pain, vomiting, fever or signs of a blocked bowel need urgent medical care.
Centers recognized for expertise in this condition, and communities of people living with it.
A listed site in the registered Phase 3 mirikizumab trials VIVID-1 and VIVID-2 and in the Phase 3 tulisokibart trial for Crohn's disease.
A listed site in the registered Phase 3 trials VIVID-1 (mirikizumab), GALAXI (guselkumab) and the tulisokibart Phase 3 for Crohn's disease.
A listed site in the registered Phase 3 trials VIVID-1, GALAXI and the tulisokibart Phase 3 for Crohn's disease.
A listed site in the registered Phase 3 trials VIVID-1, GALAXI and the tulisokibart Phase 3 for Crohn's disease.
A listed site in the registered Phase 3 trials VIVID-1, GALAXI and the tulisokibart Phase 3 for Crohn's disease.
A listed site in the registered Phase 3 trials VIVID-1, GALAXI and the tulisokibart Phase 3 for Crohn's disease.
These are centers recognized for expertise in this condition, not a ranking, and Cure Checker does not endorse or rate any facility. Outcomes depend on the individual. Ask your doctor which center fits your situation.
Crohn's can be isolating, and talking with others who live with it helps. Most of these are free.
The U.S. foundation's support-group finder lists local and online groups for patients, families and caregivers.
Find a group ↗Runs a helpline and a closed Facebook forum for anyone affected by IBD, moderated by staff on weekdays.
Visit ↗Offers peer support and caregiver groups, local chapters and education programs.
Visit ↗The International Federation of Crohn's & Ulcerative Colitis Associations links 51 national patient groups. Use it to find one in your country.
Visit ↗A large Reddit community where people share experiences about symptoms, food and medicines. Posts are personal stories, not medical advice.
Visit ↗Many private patient and caregiver groups exist. This link searches Facebook (a login is required).
Search Facebook ↗Before you join: support groups share experiences, not medical advice. Check anything about treatment with your doctor. Protect your privacy, and never share passwords or financial details. Cure Checker isn't affiliated with these groups.
The newer biologics and the daily pill are approved in the U.S. and the EU, and recommended in England. Health Canada has approved several of them. We mark only approvals we could verify.
| Treatment | U.S. | EU | UK | Canada | Japan | S. Korea | China | Australia | Switz. |
|---|---|---|---|---|---|---|---|---|---|
| Risankizumab (Skyrizi)IL-23 blocker | Approved 2022 | Approved | NICE 2023 | Approved 2022 | — | — | — | — | — |
| Upadacitinib (Rinvoq)JAK-inhibitor pill | Approved 2023 | Approved | NICE 2023 | Approved 2023 | — | — | — | — | — |
| Mirikizumab (Omvoh)IL-23 blocker | Approved 2025 | Approved | NICE 2025 | — | — | — | — | — | — |
| Guselkumab (Tremfya)IL-23 blocker | Approved 2025 | Approved | NICE 2025 | Approved 2025 | — | — | — | — | — |
| Ustekinumab (Stelara)IL-12/23 blocker | Ages 2+ in 2026 | Ages 2+ | NICE 2017 | — | — | — | — | — | — |
A Phase 3 trial that started June 5, 2024 is recruiting about 1,200 people with moderate to severe Crohn's at sites in North America, Europe and beyond. Main results are estimated for late 2028.
Two Phase 3 trials are recruiting: STARSCAPE-1 for starting treatment (about 980 people) and STARSCAPE-2 for long-term treatment (about 751 people).
A Phase 2b trial of a daily pill that works differently from current drugs is enrolling about 212 people. Main results are estimated for December 2026.
Doctors aren't sure exactly what causes Crohn's disease. Experts think the immune system overreacts to the normal bacteria in the gut, and that genes, the environment and the gut's microbes all play a part.
Live numbers and the newest entries from the world's main trial registries and medical databases. Most of this loads fresh each time you open the page.
Loading live data from ClinicalTrials.gov…
Loading…
Loading…
Loading…
| Medicine | Brand | FDA application | Original approval |
|---|
From Drugs@FDA via FDA's openFDA service. Some older brands are missing from FDA's open data, and newly approved drugs can take a few weeks to appear. An approval may be for a different disease than this one.
The WHO's ICTRP gathers trials from registries worldwide, including China, Japan, India, Iran, Australia and Brazil. Cochrane CENTRAL and OpenMD don't allow automated access, so they're linked here for you to search directly.
These organizations help people with Crohn's pay for medicines or for a child's IBD camp. Funds are limited and rules vary, so contact each one directly.
Camp Oasis is a summer camp only for kids with IBD. It has a $400 attendance fee, and scholarships and travel stipends are available to those who qualify. You request them on a form inside the camp application.
Read the camp FAQ ↗Helps with copays, coinsurance, deductibles and other health costs for an FDA-approved Crohn's treatment. On October 6, 2026 it was taking names for a waitlist, not new enrollments.
Check fund status ↗Grants toward copays, coinsurance, deductibles and insurance premiums. The fund was closed on October 6, 2026; the page lets you sign up to hear when it reopens.
Check fund status ↗Helps pay prescription copays for IBD medicines, up to $2,100. The fund was closed to new patients on October 6, 2026; you can sign up for alerts when it reopens.
Check fund status ↗Before you apply: Cure Checker does not run, verify or endorse these organizations, and being listed is not a promise of help. Funds are limited and rules change, so confirm eligibility and details with each organization. Be careful of anyone who asks for payment up front or for your bank login to 'release' a grant.
Everything this report is based on, grouped by section. Checked October 4, 2026.
FDA approval dates are the Drugs@FDA (openFDA) dates of the relevant approval letters. Not individually cited: that corticosteroids, immunosuppressants such as azathioprine, and TNF blockers (adalimumab) are standard Crohn's care, the general description of how each drug class works, and the remark that a cure would need to reset the gut's immune response, which is Cure Checker's editorial view. The "first non-TNF biologic for ages 2+" claim for Stelara and the three-year VIVID-2 results come from company or conference sources and are not yet in a peer-reviewed paper we could read. The step 1 bar is illustrative only. All "—" cells in the approvals table are unverified, including Japan, South Korea, China, Australia and Switzerland, and Omvoh and Stelara in Canada. UK cells reflect NICE recommendations for England. EU cells are taken from current EMA EPAR pages, without dates. Expert care centers: no official national designation for Crohn's disease care could be verified for this report, so centers are listed because they are sites in several registered Phase 3 trials, confirmed on ClinicalTrials.gov. r/CrohnsDisease blocks automated checks, so its existence was confirmed through search results and a published study of the community rather than by opening the page. The Crohn's & Colitis Foundation website also blocks automated checks; its support-group finder was confirmed through search results. Financial help: checked October 6, 2026, mostly with a headless browser. All three copay funds were closed or waitlisted that day, and their status changes often. The Camp Oasis page does not spell out who qualifies for a scholarship. PAN Foundation's copay funds now run through Patient Advocate Foundation's TotalAssist, so PAN is not listed on its own. Left out: Crohn's & Colitis UK (it now points to outside grant search tools rather than giving its own grants), education scholarships, and drug-company programs. We found no Crohn's charity giving its own hardship grants to individuals.